Top Page
Jinhai International Group Holdings Limited
(2225)
Jinhai International Group Holdings Limited (2225) vs. iShares MSCI Hong Kong ETF (EWH)
Jinhai International Group Holdings Limited Business Overview & Revenue Model
Jinhai International Group Holdings Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.83M | 50.24M | 45.64M | 22.28M | 21.90M | 22.47M |
| Gross Profit | 6.14M | 11.48M | 12.03M | 10.12M | 7.73M | 8.85M |
| EBITDA | -20.18M | -16.82M | 1.11M | 5.25M | 5.44M | 2.15M |
| Net Income | -22.18M | -17.96M | -3.14M | 468.00K | -246.21K | 1.26M |
Balance Sheet | ||||||
| Total Assets | 50.15M | 58.87M | 62.22M | 40.27M | 33.77M | 39.41M |
| Cash, Cash Equivalents and Short-Term Investments | 6.97M | 14.93M | 26.76M | 23.95M | 25.91M | 27.39M |
| Total Debt | 14.67M | 14.52M | 10.08M | 4.45M | 1.87M | 5.50M |
| Total Liabilities | 22.38M | 26.09M | 24.73M | 15.68M | 9.75M | 13.92M |
| Stockholders Equity | 27.36M | 31.81M | 37.47M | 24.37M | 24.28M | 25.49M |
Cash Flow | ||||||
| Free Cash Flow | -4.86M | -4.26M | -3.15M | 3.06M | 2.73M | 7.25M |
| Operating Cash Flow | -4.10M | -3.25M | -1.91M | 4.24M | 3.34M | 7.38M |
| Investing Cash Flow | -1.63M | -9.22M | -6.51M | -1.15M | -2.64M | -6.04M |
| Financing Cash Flow | 3.11M | 2.93M | 13.62M | -3.72M | -4.81M | -4.15M |
Jinhai International Group Holdings Limited Technical Analysis
Jinhai International Group Holdings Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$1.09B | 7.14 | 11.29% | 36.45% | 17.49% | 9.67% | |
| ― | HK$59.40M | 5.89 | 7.43% | ― | -11.47% | 5.00% | |
| ― | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
| ― | HK$53.21M | -5.45 | ― | ― | ― | ― | |
| ― | HK$1.62B | 10.51 | ― | ― | -10.48% | 30250.00% | |
| ― | HK$5.77B | ― | -67.70% | ― | -33.94% | -119.13% | |
| ― | HK$743.79M | ― | -4.09% | 1.85% | 14.29% | -200.37% |
Jinhai International Group Holdings Limited Corporate Events
Jinhai Medical Technology Limited, a subsidiary of Jinhai International Group Holdings, is preparing to participate in the Eighth China International Import Expo in Shanghai. At the event, Jinhai Medical, in collaboration with Medtronic China, will introduce a new navigated spinal endoscope technique aimed at enhancing precision and efficiency in spinal surgeries. This development is expected to significantly impact the field of spinal surgery by facilitating broader clinical applications and reducing the learning curve for clinicians.
The most recent analyst rating on (HK:2225) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.
Jinhai Medical Technology Limited has announced a change in its company secretary, authorised representative, and process agent roles. Ms. Cheng Yuen has resigned from these positions, effective September 29, 2025, and Mr. Wong Man Yiu has been appointed to fill the vacancies. Mr. Wong, who previously served in similar roles within the company, brings extensive experience in company secretarial practices and regulatory requirements. This change is expected to maintain the company’s compliance and operational efficiency.
The most recent analyst rating on (HK:2225) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.
Jinhai Medical Technology Limited reported a significant decline in its financial performance for the first half of 2025, with revenue dropping from S$25,937,000 in 2024 to S$14,529,000 in 2025. The company faced a loss before tax of S$10,722,000, compared to a loss of S$5,941,000 in the same period last year, indicating challenges in maintaining profitability. This downturn in financial results could impact the company’s market positioning and stakeholder confidence.
The most recent analyst rating on (HK:2225) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.
Jinhai Medical Technology Limited has issued a profit warning, anticipating a significant increase in net loss for the first half of 2025, compared to the same period in 2024. The expected loss of approximately S$10.8 million is primarily due to a decrease in gross profit, attributed to reduced revenue from its core business operations. This announcement may impact stakeholders’ perception and requires cautious consideration by investors.
The most recent analyst rating on (HK:2225) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.
Jinhai Medical Technology Limited has announced that its board of directors will convene on August 29, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. This meeting will also consider the payment of an interim dividend, which could have implications for shareholders and reflect the company’s financial health and strategic direction.
Jinhai Medical Technology Limited has successfully completed the issuance of 120,000,000 new shares under its general mandate, raising approximately HK$161.0 million in net proceeds. The funds will be used for potential mergers and acquisitions in the healthcare sector, research and development, and general working capital. This strategic move slightly dilutes existing shareholders but positions the company for growth and expansion in its industry.